Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Archives of Psychiatry and Clinical Neuroscience
Published in: European Archives of Psychiatry and Clinical Neuroscience 4/2021

01-06-2021 | Schizophrenia | Original Paper

Inflammation, hippocampal volume, and cognition in schizophrenia: results from the Northern Finland Birth Cohort 1966

Authors: Brian J. Miller, Karl-Heinz Herzig, Jari Jokelainen, Toni Karhu, Sirkka Keinänen-Kiukaanniemi, Marjo-Riitta Järvelin, Juha Veijola, Heimo Viinamäki, Päivikki Tanskanen, Erika Jääskeläinen, Matti Isohanni, Markku Timonen

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 4/2021

Login to get access

Abstract

Increased blood interleukin-6 (IL-6) levels are a replicated abnormality in schizophrenia, and may be associated with smaller hippocampal volumes and greater cognitive impairment. These findings have not been investigated in a population-based birth cohort. The general population Northern Finland Birth Cohort 1966 was followed until age 43. Subjects with schizophrenia were identified through the national Finnish Care Register. Blood IL-6 levels were measured in n = 82 subjects with schizophrenia and n = 5373 controls at age 31. Additionally, 31 patients with schizophrenia and 63 healthy controls underwent brain structural MRI at age 34, and cognitive testing at ages 34 and 43. Patients with schizophrenia had significantly higher median (interquartile range) blood IL-6 levels than controls (5.31, 0.85–17.20, versus 2.42, 0.54–9.36, p = 0.02) after controlling for potential confounding factors. In both schizophrenia and controls, higher blood IL-6 levels were predictors of smaller hippocampal volumes, but not cognitive performance at age 34. We found evidence for increased IL-6 levels in patients with midlife schizophrenia from a population-based birth cohort, and replicated associations between IL-6 levels and hippocampal volumes. Our results complement and extend the previous findings, providing additional evidence that IL-6 may play a role in the pathophysiology of schizophrenia and associated brain alterations.
Literature
1.
Nitta M, Kishimoto T, Müller N, Weiser M, Davidson M, Kane JM et al (2013) Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull 39:1230–1241PubMedPubMedCentral
2.
Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS (2014) Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 40:181–191PubMed
3.
Laan W, Grobbee DE, Selten JP et al (2010) Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 71:520–527PubMed
4.
Muller N, Ulmschneider M, Scheppach C et al (2004) COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci 254:14–22PubMed
5.
Hudson ZD, Miller BJ (2018) Meta-analysis of cytokine and chemokine genes in schizophrenia. Clin Schizophr Relat Psychoses 12:121–129PubMed
6.
Zakharyan R, Petrek M, Arakelyan A, Mrazek F, Atshemyan S, Boyajyan A (2012) Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens 80:136–142PubMed
7.
Khandaker GM, Zammit PRM, et al (2014) Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 71:1121–1128PubMedPubMedCentral
8.
Khandaker GM, Zammit S, Burgess S et al (2018) Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort. Brain Behav Immun 69:264–272PubMedPubMedCentral
9.
Stojanovic A, Martorell L, Montalvo I, Ortega L, Monseny R, Vilella E, Labad J (2014) Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology 41:23–32PubMed
10.
Goldsmith D, Rapaport MH, Miller BJ (2016) Meta-analysis of cytokine alterations in Psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Mol Psychiatry 21:1696–1709PubMedPubMedCentral
11.
Wang AK, Miller BJ (2018) Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophr Bull 44:75–83PubMed
12.
Chase KA, Cone JJ, Rosen C et al (2016) The value of interleukin 6 as a peripheral diagnostic marker in schizophrenia. BMC Psychiatry 16:152PubMedPubMedCentral
13.
Dimitrov DH, Lee S, Yantis J et al (2013) Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway. Schizophr Res 151:29–35PubMed
14.
Frommberger UH, Bauer J, Haselbauer P et al (1997) Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 247:228–233PubMed
15.
Pae CU, Yoon CH, Kim TS, Kim JJ, Park SH, Lee CU, Lee SJ, Lee C, Paik IH (2006) Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. Int Immunopharmacol 6:666–671PubMed
16.
Gadient RA, Otten U (1994) Expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) mRNAs in rat brain during postnatal development. Brain Res 637:10–14PubMed
17.
Doremus-Fitzwater TL, Gano A, Paniccia JE et al (2015) Male adolescent rats display blunted cytokine responses in the CNS after acute ethanol or lipopolysaccharide exposure. Physiol Behav 148:131–144PubMedPubMedCentral
18.
Gibney SM, McGuinness B, Prendergast C et al (2013) Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav Immun 28:170–181PubMed
19.
Murray C, Griffin ÉW, O'Loughlin E et al (2015) Interdependent and independent roles of type I interferons and IL-6 in innate immune, neuroinflammatory and sickness behaviour responses to systemic poly I:C. Brain Behav Immun 48:274–286PubMedPubMedCentral
20.
Bellinger FP, Madamba SG, Campbell IL et al (1995) Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. Neurosci Lett 198:95–98PubMed
21.
Heyser CJ, Masliah E, Samimi A et al (1997) Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci USA 94:1500–1505PubMed
22.
Monje ML, Toda H, Palmer TD (2003) Inflammatory blockade restores adult hippocampal neurogenesis. Science 302:1760–1765PubMed
23.
Braida D, Sacerdote P, Panerai AE et al (2004) Cognitive function in young and adult IL (interleukin)-6 deficient mice. Behav Brain Res 153:423–429PubMed
24.
Sparkman NL, Buchanan JB, Heyen JR et al (2006) Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. J Neurosci 26:10709–10716PubMedPubMedCentral
25.
Harrison NA, Cercignani M, Voon V et al (2015) Effects of inflammation on hippocampus and substantia nigra responses to novelty in healthy human participants. Neuropsychopharmacology 40:831–838PubMed
26.
Patel A, Zhu Y, Kuzhikandathil EV et al (2012) Soluble interleukin-6 receptor induces motor stereotypies an co-localizes with gp130 in regions linked to cortico-striato-thalamo-cortical circuits. PLoS ONE 7:e41623PubMedPubMedCentral
27.
Marsland AL, Gianaros PJ, Abramowitch SM et al (2008) Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry 64:484–490PubMedPubMedCentral
28.
Frodl T, Carballedo A, Hughes MM, Saleh K, Fagan A, Skokauskas N et al (2012) Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. Transl Psychiatry 2:e88PubMedPubMedCentral
29.
Kakeda S, Watanabe K, Katsuki A et al (2018) Relationship between interleukin (IL)-6 and brain morphology in drug-naïve, first-episode major depressive disorder using surface-based morphometry. Sci Rep 8:10054PubMedPubMedCentral
30.
Kalmady SV, Venkatasubramanian G, Shivakumar V, Gautham S, Subramaniam A, Jose DA et al (2014) Relationship between Interleukin-6 gene polymorphism and hippocampal volume in antipsychotic-naïve schizophrenia: evidence for differential susceptibility? PLoS ONE 9:e96021PubMedPubMedCentral
31.
Mondelli V, Cattaneo A, Murri MB et al (2011) Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry 72:1677–1684PubMedPubMedCentral
32.
Hoseth EZ, Westlye LT, Hope S et al (2016) Association between cytokine levels, verbal memory and hippocampus volume in pscyhotic disorders and healthy controls. Acta Psychiatr Scand 133:53–62PubMed
33.
Handley R, Mondelli V, Zelaya F et al (2016) Effects of antipsychotics on cortisol, interleukin-6 and hippocampal perfusion in healthy volunteers. Schizophr Res 174:99–105PubMed
34.
Cannon TD, Chung Y, He G et al (2015) North American Prodrome Longitudinal Study Consortium Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatry 77:147–157PubMed
35.
Lim A, Krajina K, Marsland AL (2013) Peripheral inflammation and cognitive aging. Mod Trends Pharmacopsychiatry 28:175–187PubMed
36.
Marsland AL, Kuan DCH, Dheu LK et al (2017) Systemic inflammation and resting state connectivity of the default mode network. Brain Behav Immun 62:162–170PubMedPubMedCentral
37.
Reichenberg A, Yirmiya R, Schuld A et al (2001) Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58:445–452PubMed
38.
Brydon L, Harrison NA, Walker C et al (2008) Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol Psychiatry 63:1022–1029PubMedPubMedCentral
39.
Krabbe KS, Reichenberg A, Yirmiya R et al (2005) Low-dose endotoxemia and human neuropsychological functions. Brain Behav Immun 19:453–460PubMed
40.
Späth-Schwalbe E, Hansen K, Schmidt F et al (1998) Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 83:1573–1579PubMed
41.
Marsland AL, Petersen KL, Sathanoori R et al (2006) Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers. Psychosom Med 68:895–903PubMed
42.
Mooijaart SP, Sattar N, Trompet S et al (2013) Circulating interleukin-6 concentration and cognitive decline in old age, the PROSPER study. J Intern Med 274:77–85PubMed
43.
Elderkin-Thompson V, Irwin MR, Hellemann G, Kumar A (2012) Interleukin-6 and memory functions of encoding and recall in healthy and depressed elderly adults. J Geriatr Psychiatry 20:753–763
44.
Sasayama D, Hori H, Teraishi T, Hattori K, Ota M, Matsuo J et al (2012) Association of cognitive performance with interleukin-6 receptor Asp358Ala polymorphism in healthy adults. J Neural Transm 119:313–318PubMed
45.
Miller B, Mellor A, Buckley PF (2013) Interleukin-6 and cognition in non-affective psychosis. Schizophr Bull 39:S242–S243
46.
Frydecka D, Misiak B, Pawlak-Adamska E, Karabon L, Tomkiewicz A, Sedlaczek P et al (2015) Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation. Eur Arch Psychiatry Clin Neurosci 262:449–459
47.
Aas M, Mondelli V, Toulopoulou T, et al. (2010) Is inflammation linked to cognitive impairment in first-episode psychosis and in healthy controls? 17th Annual Meeting of The Psychoneuroimmunology Research Society: Crossing Disciplines to Combat Disease, Dublin.
48.
Fillman SG, Cloonan N, Catts VS et al (2013) Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 18:206–214PubMed
49.
Volk DW, Chitrapu A, Edelson JR et al (2015) Molecular mechanisms and timing of cortical immune activation in schizophrenia. Am J Psychiatry 172:1112–1121PubMedPubMedCentral
50.
Lanz TA, Reinhart V, Sheehan MJ et al (2019) Postmortem transcriptional profiling reveals widespread increase in inflammation in schizophrenia: a comparison of prefrontal cortex, striatum, and hippocampus among matched tetrads of controls with subjects diagnosed with schizophrenia, bipolar or major depressive disorder. Transl Psychiatry 9:151PubMedPubMedCentral
51.
Hope S, Hoseth E, Dieset I et al (2015) Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls. Schizophr Res 165:188–194PubMed
52.
Hori H, Yoshimura R, Katsuki A et al (2017) Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy. World J Biol Psychiatry 18:401–408PubMed
53.
Fillman SG, Weickert TW, Lenroot RK et al (2016) Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca’s area volume. Mol Psychiatry 21:1090–1098PubMed
54.
Meyer U, Schwarz MJ, Müller N (2011) Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther 132:96–110PubMed
55.
Khandaker GM, Cousins L, Deakin J et al (2015) Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2:258–270PubMedPubMedCentral
56.
Zhang L, Zheng H, Wu R et al (2019) The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia. Schizophr Res 212:92–98PubMed
57.
Miller BJ, Dias JK, Lemos HP et al (2016) An open-label, pilot trial of adjunctive tocilizumab in schizophrenia. J Clin Psychiatry 77:275–276PubMed
58.
Girgis RR, Ciarleglio A, Choo T et al (2018) A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia. Neuropsychopharmacology 43:1317–1323PubMed
59.
Jääskeläinen E, Haapea M, Rautio N et al (2015) Twenty years of schizophrenia research in the Northern Finland Birth Cohort 1966: a systematic review. Schizophr Res Treat 2015:524875
60.
Sorri M, Järvelin M-R (1998) Well-being and health Background to the Northern Finland 1966 birth cohort research. Int J Circumpolar Health 57:82–83PubMed
61.
Johansson-Persson A, Ulmius M, Cloetens L, Karhu T, Herzig KH, Onning G (2014) A high intake of dietary fiber influences C-reactive protein and fibrinogen, but not glucose and lipid metabolism, in mildly hypercholesterolemic subjects. Eur J Nutr 53:39–48PubMed
62.
Meriläinen S, Mäkelä J, Jensen HA et al (2012) Portal vein cytokines in the early phase of acute experimental oedematous and necrotizing porcine pancreatitis. Scand J Gastroenterol 47:1375–1385PubMed
63.
Lajunen TK, Purhonen AK, Haapea M et al (2012) Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome. Eur J Clin Invest 42:321–328PubMed
64.
Arajärvi R, Suvisaari J, Suokas J et al (2005) Prevalence and diagnosis of schizophrenia based on register, case record and interview data in an isolated Finnish cohort born 1940–1969. Soc Psychiatry Psychiatr Epidemiol 40:808–816PubMed
65.
Isohanni M, Makikyro T, Moring J et al (1997) A comparison of clinical and research DSM-III-R diagnoses of schizophrenia in a Finnish national birth cohort Clinical and research diagnoses of schizophrenia. Soc Psychiatry Psychiatr Epidemiol 32:303–308PubMed
66.
Moilanen K, Veijola J, Laksy K et al (2003) Reasons for the diagnostic discordance between clinicians and researchers in schizophrenia in the Northern Finland 1966 Birth Cohort. Soc Psychiatry Psychiatr Epidemiol 38:305–310PubMed
67.
Cook MJ (1994) Mesial temporal sclerosis and volumetric investigations. Acta Neurol Scand 152:109–114
68.
Laakso MP, Tiihonen J, Syvahti E et al (2001) A morphometric MRI study of the hippocampus in first-episode, neuroleptic-naive schizophrenia. Schizophr Res 30:3–7
69.
Suckling J, Brammer MJ, Lingford-Hughes A et al (1999) Removal of extracerebral tissues in dual-echo magnetic resonance images via linear scale-space features. Magn Reson Imaging 17:247–256PubMed
70.
Ridler K, Veijola JM, Tanskanen P et al (2006) Fronto-cerebellar systems are associated with infant motor and adult executive functions in healthy adults but not in schizophrenia. Proc Natl Acad Sci USA 103:15651–15656PubMed
71.
Tanskanen P, Veijola J, Piippo U, Haapea M, Miettunen J, Pyhtinen J, Bullmore ET, Jones PB, Isohanni M (2005) Hippocampus and amygdala volumes in schizophrenia and other psychoses in the Northern Finland 1966 Birth Cohort. Schizophr Res 75:283–294PubMed
72.
Delis DC, Kramer JH, Kaplan E, Ober BA (1987) The California verbal learning test: Research edition, adult version. The Psychological Corporation, San Antonio, TX
73.
Rannikko I, Haapea M, Miettunen J et al (2015) Changes in verbal learning and memory in schizophrenia and non-psychotic controls in midlife: a nine-year follow-up in the Northern Finland Birth Cohort study 1966. Psychiatry Res 228:671–679PubMed
74.
Kelly C, McEvoy JP, Miller BJ (2019) Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Schizophr Res 209:193–197PubMed
75.
Kirkpatrick B, Miller B, Garcia-Rizo C et al (2012) Is glucose tolerance in antipsychotic-naïve nonaffective psychosis confounded by poor health habits? Schizophr Bull 38:280–284PubMed
76.
Miller BJ, Buckley PF, McEvoy JP (2018) Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Schizophr Res 195:275–282PubMed
77.
78.
Moody G, Miller BJ (2018) Total and differential white blood cell counts and hemodynamic parameters in first-episode psychosis. Psychiatry Res 260:307–312PubMed
79.
Dieset I, Haukvik UK, Melle I et al (2015) Association between altered brain morphology and elevated peripheral endothelial markers–implications for psychotic disorders. Schizophr Res 161:222–228PubMed
80.
Lesh TA, Rose CM, et al (2018) Cytokine alterations in first-episode schizophrenia and bipolar disorder: relationships to brain structure and symptoms. J Neuroinflammation 15:165PubMedPubMedCentral
81.
Prasad KM, Upton CH, Nimgaonkar VL et al (2015) Differential susceptibility of white matter tracts to inflammatory mediators in schizophrenia: an integrated DTI study. Schizophr Res 161:119–125PubMed
82.
83.
Baldi E, Bucherelli C (2005) The inverted “u-shaped” dose-effect relationships in learning and memory: modulation of arousal and consolidation. Nonlinearity Biol Toxicol Med 3:9–21PubMedPubMedCentral
84.
Baune BT, Konrad C, Grotegerd D et al (2012) Interleukin-6 gene (IL-6): a possible role in brain morphology in the healthy adult brain. J Neuroinflamm 9:125
85.
Stenfors CUD, Jonsdottir IH, Magnusson Hanson LL et al (2017) Associations between systemic pro-inflammatory markers, cognitive function and cognitive complaints in a population-based sample of working adults. J Psychosom Res 96:49–59PubMed
86.
Martínez-Cengotitabengoa M, Mac-Dowell KS, Leza JC et al (2012) Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res 137:66–72PubMed
87.
Zalcman S, Green-Johnson JM, Murray L et al (1994) Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 643:40–49PubMed
88.
Zalcman S, Savina I, Wise RA (1999) Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats. Brain Res 847:276–283PubMed
89.
Gaspar PA, Bustamante ML, Silva H et al (2009) Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications. J Neurochem 111:891–900PubMed
90.
Maier S, Watkins LR (1998) Cytokines for psychologists: implications of bidirectionalimmune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 105:83–107PubMed
91.
Haapea M, Miettunen J, Läärä E, Joukamaa M, Järvelin M-R, Isohanni M, Veijola J (2008) Non-participation in a field survey with respect to psychiatric disorders. Scand J Public Health 36:728–736PubMed
92.
Hurtz S, Chow N, Watson AE et al (2019) Automated and manual hippocampal segmentation techniques: comparison of results, reproducibility and clinical applicability. Neuroimage 21:101574PubMed
93.
Wenger E, Martensson J, Noack H et al (2014) Comparing manual and automatic segmentation of hippocampal volumes: reliability and validity issues in younger and older brains. Hum Brain Mapp 35:4236–4248PubMedPubMedCentral
94.
O’Connor M et al (2009) To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. Brain Behav Immun 23:887–897PubMedPubMedCentral
Metadata
Title
Inflammation, hippocampal volume, and cognition in schizophrenia: results from the Northern Finland Birth Cohort 1966
Authors
Brian J. Miller
Karl-Heinz Herzig
Jari Jokelainen
Toni Karhu
Sirkka Keinänen-Kiukaanniemi
Marjo-Riitta Järvelin
Juha Veijola
Heimo Viinamäki
Päivikki Tanskanen
Erika Jääskeläinen
Matti Isohanni
Markku Timonen
Publication date
01-06-2021
Publisher
Springer Berlin Heidelberg
Keyword
Schizophrenia
Published in
European Archives of Psychiatry and Clinical Neuroscience / Issue 4/2021
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-020-01134-x

Other articles of this Issue 4/2021

European Archives of Psychiatry and Clinical Neuroscience 4/2021 Go to the issue

Original Paper

The network structure of schizotypy in the general population

Original Paper

Genetic risks of schizophrenia identified in a matched case–control study

Original Paper

Brain activity and connectivity differences in reward value discrimination during effort computation in schizophrenia

Original Paper

Three types of psychotic-like experiences in youth at clinical high risk for psychosis

Original Paper

Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: a multi-modal PET and 1H-MRS study

Original Paper

Increased regional homogeneity modulated by metacognitive training predicts therapeutic efficacy in patients with schizophrenia